Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 12 September 2017

Indication(s)

ZOSTAVAX is indicated for prevention of herpes zoster (“zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN).

ZOSTAVAX is indicated for immunization of individuals 50 years of age or older.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hypogonadism

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more.

+ 1 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000674
Orphan designation No
Date First Approved 19-05-2006
Type Medicinal product subject to medical prescription
Marketing authorisation holder MSD VACCINS